Description
Carbokast – 150
Composition: Carboplatin Injection IP
Classification: Anticancer Medicine
Carbokast–150 is a sterile formulation containing carboplatin 10 mg/mL, to be diluted for intravenous infusion.
Aprazer Healthcare: Innovating Oncology with Impact
Backed by Aprazer Healthcare’s global mission for affordable oncology care, Carbokast 150 has been developed with precision, efficacy, and safety to deliver quality care worldwide.
Carbokast–150 (Carboplatin) has Proven Efficacy in Treating:
- • Initial and advanced stage ovarian cancers
- • As palliative treatment for recurrent cancers
- • It is used alone or in combination for the unresponsive cancers
- • Used in preparatory (conditioning) regimens before bone marrow or stem cell transplantation
It is Also Used to Treat:
Lung cancer, bladder cancer, breast cancer, head, neck, cancer of the cervix and testicles and brain tumors.
Mechanism of Action of Carbokast
Carboplatin inhibits DNA synthesis by crosslinking DNA strands, causing programmed cell death.
Stability
- • Carbokast – 150 unopened vial is stable till the date mentioned on the package when stored at 25°C (77°F).
- • Protect from light.
- • Solutions for infusion should be discarded 8 hours after preparation.
Caution While Handling
- • Due to its cytotoxic nature, carboplatin should be handled wearing gloves to remove dermal absorption risk.
- • If carboplatin injection comes into contact with skin or mucous membranes, it should be immediately washed with water.
- • Needles or intravenous sets made of aluminum should not be used as they precipitate carboplatin and cause a loss of potency.
Important Safety Note
To be used under the supervision of a specialty care physician and recommended to monitor during and after the therapy.
Bone marrow suppression is a dose-dependent and dose-limiting toxicity.
Peripheral blood counts should be frequently monitored during carboplatin treatment and, when appropriate, until recovery is achieved
Contraindications
Carbokast should be administered cautiously in patients –
- • With a prior history of hypersensitivity to cisplatin or any other platinum-containing compound.
- • Having bone marrow suppression or profound bleeding.
Toxicities
- • Dose limiting Toxicities- Bone marrow suppression, neutropenia, thrombocytopenia, and anemia.
- • Dose-dependent renal tubule toxicity- Requires dose adjustment based on creatinine clearance.
- • Ototoxicity- in pediatric and elderly patients
- • Electrolyte Imbalance- hypomagnesaemia, hypokalemia, hypocalcaemia
Precautions
To be cautiously used in –
- • Patients with renal insufficiency and significant bleeding.
- • Pregnant/breastfeeding mothers
General Side Effects
- • Nausea
- • Vomiting
- • Hair loss
- • Numbness, tingling sensation
- • Pain or burning in hands and feet
